Shire, 2 generics-makers settle litigation tied to Intuniv

04/26/2013 | Reuters

Shire settled all litigation with Watson Pharma and Actavis regarding its attention-deficit/hyperactivity disorder treatment Intuniv. Under the settlement, Actavis can produce and market its generic copy of the drug in the U.S. starting Dec. 1, 2014, while Watson could follow with its version 181 days after the release of Actavis' version.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC